Application of centipeda minima ethanol extract in preparation of medicine for promoting killer CD8 + T cell infiltration solid tumor

Activation of cGAS/STING/TBK1/IRF3 signaling pathway through goose herbivorous ethanol extract, promoting CD8+ T cell infiltration, solving the problem of poor response of lung cancer immunotherapy to 'cold tumors', significantly improving the tumor immune response, and providing new lung cancer treatment strategy.

CN118924802APending Publication Date: 2024-11-12GUANGZHOU UNIVERSITY OF CHINESE MEDICINE +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411214826.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing lung cancer immunotherapy is poor in most lung cancer patients, especially the 'cold tumor' state caused by low CD8+ T lymphocyte infiltration, which makes it difficult to effectively activate the immune response.

Method used

Activate the cGAS/STING/TBK1/IRF3 signaling pathway through goose herbivorous ethanol extract, induce type I interferon gene expression, promote CD8+ T cells infiltrate solid tumors, transform 'cold tumors' into 'hot tumors', and activate innate immune responses .

Benefits of technology

Goose herbivorous ethanol extract significantly increases the infiltration and activation of CD8+ T cells in tumor tissues, improves the tumor immune microenvironment, provides new auxiliary strategies for tumor immunotherapy, and enhances resistance to lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924802A_ABST
    Figure CN118924802A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and particularly discloses an application of a centipeda minima ethanol extract in preparation of a medicine for promoting killer CD8 + T cells to infiltrate solid tumors, compared with the prior art, the centipeda minima ethanol extract induces expression of an I-type interferon gene by activating a cGAS / STING / TBK1 / IRF3 signal channel so as to promote the CD8 + T cells to infiltrate the solid tumors, and the application of the centipeda minima ethanol extract in preparation of the medicine for promoting killer CD8 + T cells to infiltrate the solid tumors is disclosed. The innate immune response is activated. The medicine has the characteristics of converting an immune'cold tumor 'into an immune'hot tumor' and remodeling a tumor immune microenvironment; therefore, the centipeda minima ethanol extract can be used for preparing the medicine for promoting killer CD8 + T cells to infiltrate solid tumors, and a new strategy can be provided for assisting tumor immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, in particular to the use of ethanol extract of scutellaria baicalensis in the preparation of drugs that promote the killing of CD8 + Application of drugs to T cell infiltration in solid tumors. Background Art

[0002] Cancer is the second leading cause of death in the world. According to the 2023 Cancer Report, lung cancer ranks second in prevalence and first in mortality among tumors in 2023. Although tumor targeted and immunotherapy have made rapid progress, the five-year survival rate of lung cancer patients worldwide is still less than 20%.

[0003] Current clinical immune checkpoint blockade therapies, including cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) immune checkpoint blockers, can activate the autoimmune system in cancer patients to exert a sustained and powerful anti-tumor immune response. However, immunotherapy is only suitable for about 20%-40% of cancer patients and has immune-related toxic side effects. + T lymphocytes have low infiltration levels in many tumors, i.e., immune “cold tumor” state, which leads to poor clinical response of tumor patients to immune checkpoint blockade therapy. + T lymphocyte infiltration and promoting the transformation of immune "cold tumors" into "hot tumors" has become a new anti-tumor immunotherapy strategy.

[0004] Innate immunity is the first line of defense in mammals. The latest research results show that a cancer-intrinsic innate immune signaling GMP-AMP synthase (cGAS) recognition receptor plays a key role in initiating anti-tumor immune responses. After recognizing cytoplasmic DNA fragments, the receptor produces cyclic GMP-AMP (cGAMP) to trigger the innate immune response. cGAMP binds to and activates the stimulator of interferon genes (STING), prompting STING to form a tetramer, which further promotes TBK1 phosphorylation and recruits the activating transcription factor IRF3. IRF3 promotes the expression of type I interferon (IFN-I) genes and other interferon-stimulated genes (ISG). Among them, type I interferon genes include genes such as IFN-β and IFN-α. Therefore, the cGAS-STING pathway mainly promotes tumor antigen presentation and cytotoxic CD8 by inducing the secretion of factors such as IFN-I and ISG in the tumor microenvironment. + The recruitment and activation of T lymphocytes play an important role in anti-tumor immunity.

[0005] Traditional Chinese medicine has unique advantages in regulating tumor immunity, which can significantly improve the quality of life of cancer patients while alleviating their symptoms. Centipeda minima (L.) A. Braun & Asch is the dried whole herb of the Asteraceae plant, also known as stone coriander, scattered star grass, mosquito grass, etc. It is warm in nature, spicy in taste, belongs to the lung meridian, has the functions of dispersing wind and cold, clearing the nasal passages, and relieving cough. It is also used in folk medicine to treat nasopharyngeal carcinoma. There are few reports on the regulation of anti-tumor immunity and the induction of innate immune response by Centipeda minima.

[0006] Chinese patent application number CN202010395134.3 discloses an anticancer drug and compound for regulating the expression of PD-L1 and its application. Specifically, the present invention provides the application of the Chinese medicine Goose does not eat grass in the preparation of a drug for regulating the expression of PD-L1. The present invention also provides the application of the Chinese medicine Goose does not eat grass alone or in combination with other drugs in the preparation of a drug with anti-lung cancer activity.

[0007] This scheme verifies that the aqueous extract of goosegrass can be used to prepare auxiliary drugs to enhance PD-1 targeted drugs or PD-L1 targeted drugs, but it does not reveal that the ethanol extract of goosegrass can promote the killing of CD8 + T cell infiltration of solid tumors. Summary of the invention

[0008] In order to solve the above technical problems, the present invention provides a method for preparing a kind of ethanol extract of acanthocephala for promoting cytotoxicity of CD8 + Application of drugs to T cell infiltration in solid tumors.

[0009] To achieve the above object, the present invention is implemented according to the following technical solutions:

[0010] One of the purposes of the present invention is to provide a method for preparing a kind of ethanol extract of aphidaceae for promoting killing CD8 + The application of ethanol extract of goosegrass in the treatment of T cell infiltration of solid tumors can induce the expression of type I interferon genes by activating the cGAS / STING / TBK1 / IRF3 signaling pathway, thereby promoting CD8 + T cell infiltration of solid tumors.

[0011] Furthermore, the preparation method of the ethanol extract of the Herba Lysimachiae is as follows:

[0012] S1. Add the dried sample powder of the whole herb of Goosegrass into anhydrous ethanol at a ratio of 1 g: 6 mL, soak overnight, and then perform ultrasonic extraction for 1 hour. After filtering the residue, the extract is collected into another conical flask;

[0013] S2, collect the filtered drug residue into the original conical flask and add anhydrous ethanol and then ultrasonically extract again for 1 hour, filter the drug residue and collect the extract;

[0014] S3. Repeat step S2 twice, combine the three extracts, place the extracts in a vacuum rotary evaporator to reduce pressure and recover ethanol, concentrate to a thick paste, and then use a vacuum freeze dryer to dry it into an extract to obtain an ethanol extract of Herba Lysimachiae.

[0015] The second purpose of the present invention is to provide a method for promoting the killing of CD8 + The drug for T cell infiltration of solid tumors comprises an ethanol extract of Herba Lysimachiae and a pharmaceutically acceptable excipient / carrier.

[0016] Furthermore, the medicine is one of oral liquid, pills, tablets, syrup, and film.

[0017] Compared with the prior art, the present invention discloses that the ethanol extract of ophiopogon aviculare induces the expression of type I interferon gene by activating the cGAS / STING / TBK1 / IRF3 signaling pathway, thereby promoting CD8 + T cells infiltrate solid tumors, activate innate immune responses, transform immune "cold tumors" into immune "hot tumors", and play a role in reshaping the tumor immune microenvironment, providing a new strategy for adjuvant tumor immunotherapy. + Drugs that target T cells infiltrating solid tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The ethanol extract of Escherichia coli (ECM) was analyzed by ultra performance liquid chromatography-mass spectrometry (UPLC-MS) to obtain the spectra: A is the UPLC-MS graph of 8 standards in positive ion mode, B is the UPLC-MS graph of 8 standards in negative ion mode, C is the UPLC-MS graph of ECM samples in positive ion mode, and D is the UPLC-MS graph of ECM samples in negative ion mode; among them: 1. chlorogenic acid (CA, molecular weight 354.0951); 2. rutin (molecular weight 610.1534); 3. isochlorogenic acid B (ICA-B, molecular weight 516.1268); 4. isochlorogenic acid A (ICA-A, molecular weight 516.1268); 5. isochlorogenic acid C (ICA-C, molecular weight 516.1268); 6. arnicolide D (ArD, molecular weight 332.1624); 7. arnicolide C (ArC, molecular weight 344.1780); 8. brevilinA (BA, molecular weight 346.1780).

[0019] Figure 2 Ethanol extract of goosegrass (ECM) enhances CD8 in vivo +T cell infiltration effect diagram in tumor tissue: A is the statistical diagram of tumor volume after administration of different doses of ECM; B is the statistical diagram of mouse body weight after administration of different doses of ECM; C is the flow cytometric analysis of CD8 + T cells and activated CD8 + The proportion of T cells (CD69 positive) was detected by flow cytometry. + / Gr1 + ) ratio; *P<0.05, **P<0.01, ***P<0.001.

[0020] Figure 3 Figure 3 is an analysis of the innate immune response activated by the ethanol extract of goosegrass (ECM) in vivo: A is GO analysis of the cell biological processes affected by ECM; B is the significant enrichment of genes related to innate immune response in ECM-treated tumor tissues after GSEA analysis, P < 0.05; C is a gene expression calorimeter diagram showing the effects of ECM on T cell activation and IFN-I related gene expression; D is real-time quantitative PCR detection of the effects of ECM on CD8, CD69, and CXCL10 gene expression in tumor tissues; **P < 0.01.

[0021] Figure 4 The ethanol extract of goosegrass (ECM) promotes the activation of cGAS / STING / TBK1 / IRF3 signaling pathway in lung cancer cells in vitro and increases the expression of type I interferon genes IFN-β1 and IFN-α2. The following figures show the effect of: A and B are immunoblots showing the phosphorylation of TBK1 and IRF3 proteins in NSCLC cells; C is the expression of IFN-β1 and IFN-α2 genes in LLC cells; *P<0.05, **P<0.01, ***P<0.001.

[0022] Figure 5 The ethanol extract of goosegrass (ECM) enhances the induction of LLC cells into CD8 + The effect of different doses of ECM on the migration of primary CD8 + T cell activity inhibition rate for 48 hours; B is the Transwell co-culture experiment to detect CD8 + T cell migration rate; **P<0.01, ***P<0.001. DETAILED DESCRIPTION

[0023] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not used to limit the invention.

[0024] Example 1. Preparation of Ethanol Extract of Echinops edulis (ECM)

[0025] In this embodiment, the whole herb of goose grass is sourced from Beijing Tong Ren Tang Pharmacy, and its origin is Hubei. The specific method for preparing ECM is as follows: weigh 500g of the dry sample powder of the whole herb of goose grass, add 3L of anhydrous ethanol, soak overnight, use ultrasonic extraction for 1 hour, and collect the extract in another conical flask after filtering the residue. The filtered residue is collected in the original conical flask and ultrasonically extracted again for 1 hour after adding anhydrous ethanol, filter the residue, and collect the extract; extract twice, combine the 3 extracts, place in a vacuum rotary evaporator to reduce pressure and recover ethanol, concentrate to a thick paste, and dry with a vacuum freeze dryer to an extract, and obtain about 50g of goose grass ethanol extract, which is placed in a 4°C refrigerator and sealed for standby use. In the in vitro experiment, DMSO was used to dissolve the ethanol extract of goose grass to obtain a solution with a concentration of 20mg / mL, which was stored at -20°C. The main components of the ethanol extract of goose grass were analyzed by UPLC-MS according to the standard, and the steps are as follows:

[0026] (1) Preparation of sample solution: Accurately weigh 2 mg of ethanol extract of goosegrass, add 1 mL of methanol and dissolve by ultrasonic at room temperature for 20-30 min. Sterilize the solution by filtering it through a 0.22 μm (injection needle type) filter membrane, transfer it to a sample bottle and store it in the dark to obtain the injection solution.

[0027] (2) UPLC conditions: The chromatographic column was Shim-pack GISS-C18 column (2.1×100 mm, 1.9 μm).

[0028] The mobile phase was: A: 0.1% acetic acid B: acetonitrile (v / v), and the gradient elution program was shown in Table 1.

[0029] Table 1 Gradient elution program

[0030]

[0031] Flow rate: 0.2mL / min; column temperature: room temperature; injection volume: 2μL; detection wavelength: 254nm.

[0032] (3) IT-TOF MS analysis conditions: The mass spectrometer was a Shimadzu electrospray ion trap / time-of-flight mass spectrometer (IT-TOF MS). The mass spectrometer parameters were set as follows: nebulizer (N2) and dry gas (N2) flow rates were 1.5 L / min, probe voltage was 4.50 kV in positive ion mode, -3.50 kV in negative ion mode, detector voltage was 1.56 kV, scanning mode was positive and negative ion primary scanning, acquisition range was 150-800 m / z, ion accumulation time was 50 ms, CID parameters were set to collision energy 50%, and collision gas (Ar) was 50%.

[0033] Depend on Figure 1 It can be seen that ECM contains the following main components: chlorogenic acid, rutin, isochlorogenic acid B, isochlorogenic acid A, isochlorogenic acid C, arnicolide D, arnicolide C and brevilin A.

[0034] In the following examples, the in vivo experiments were reviewed by the Experimental Animal Ethics Committee of Guangzhou University of Chinese Medicine and met the requirements of the "Regulations on Ethical Review of Animal Experiments of Guangzhou University of Chinese Medicine". When ECM was administered, anhydrous ethanol was first used to dissolve the drug, and then corn oil was used to dissolve it, and the volume ratio of anhydrous ethanol was 10%. The dissolution concentration of the ethanol extract of goose grass was 40mg / mL and 80mg / mL when administered in vivo, corresponding to the ECM 400mg / kg and ECM 800mg / kg administration groups, respectively, and the mouse administration volume was 10μL / g. The drug was prepared and used immediately, and was administered by gavage.

[0035] 1. In vivo experiments

[0036] Example 2: ECM promotes cytotoxic CD8 in vivo + Validation of T cell infiltration into solid tumors

[0037] To verify the ability of ECM to regulate tumor immunity in vivo, mouse Lewis lung cancer cells LLC (purchased from the Chinese Academy of Sciences Cell Bank) were subcutaneously inoculated into C57BL / 6 mice (purchased from Guangdong Medical Experimental Animal Center). 3 Three groups were set up: solvent control (10% anhydrous ethanol + 90% corn oil solution), ECM 400mg / kg, and ECM 800mg / kg, and the drug intervention lasted for 14 days. During the drug intervention period, the tumor volume and body weight were measured every two days. The formula for calculating the tumor volume is: (length × width 2 ) / 2. After 14 days, the mice were killed by excessive anesthesia, and the subcutaneous tumors were removed for experiments. Figure 2 As shown in A, the average tumor size of the ECM-treated mice was significantly lower than that of the control group, which shows that ECM has the effect of inhibiting tumor growth. Figure 2 B in the figure shows that there was no significant change in the body weight of mice in the ECM-treated group compared with the control group, indicating that ECM had no obvious toxic side effects on mice.

[0038] The proportion of immune cells in tumor tissue was analyzed by flow cytometry. First, a single cell suspension was obtained by digestion with tumor tissue digestion solution, which contained collagenase I (Coll I, 0.5 mg / mL), collagenase IV (Coll IV, 0.5 mg / mL) and collagenase II (Coll II, 0.1 mg / mL), and DNase I (0.1 mg / mL) was added to extract tumor cells. The single cell suspension was stained with CD45 (Cat. No. E-AB-F1136UQ), CD3 (Cat. No. E-AB-F1013UJ), CD8 (Cat. No. E-AB-F1104UE) produced by Elabscience, and CD69 (Cat. No. 39443) produced by Cell Signaling Technology, and then CD8 in tumor tissue was detected by flow cytometry. + / CD3 + T cells and CD69 + / CD8 + The proportion of T cells; at the same time, the Cd11b (E-AB-F1081E) and Gr1 (E-AB-F1120D) antibodies produced by Elabscience were used for staining, and then the MDSCs (Cd11b + / Gr1 + ) The proportion of cells changes. Figure 2 C in Figure 2 As shown in D, ECM can increase the activation of CD8 + T cells infiltrate tumors and reduce the proportion of MDSCs cells.

[0039] To explore the anti-tumor mechanism of ECM in vivo, mouse LLC cells were further inoculated subcutaneously in C57 mice. 3 ECM was administered at a dose of 800 mg / kg for 14 days, and then subcutaneous tumor-bearing tissues of the animals were taken for RNA sequencing (RNA-seq), and the sequencing data were analyzed by clustering heat map, GO (Gene Ontology) enrichment map and GSEA (Gene Set Enrichment Analysis). This RNA-seq project used the DNBSEQ platform and third-generation sequencing technology to analyze the total mRNA expression in tumor tissue samples, and used the "Dr.Tom Multi-omics Data Mining System" independently developed by BGI to analyze differentially expressed genes. Figure 3 A and Figure 3 B in the figure shows that GO and GESA analysis revealed that the innate immune response-related pathways were significantly enriched in tumor tissues after ECM treatment; Figure 3C in the figure shows that ECM can increase the expression of genes related to T cell activation factors and type I interferon (IFN-I); Figure 3 D in the figure shows that real-time quantitative PCR verification found that ECM can increase the expression of CD8, CD69, and CXCL10 genes.

[0040] 2. In vitro experiments

[0041] Example 3: ECM promotes the activation of the cGAS / STING / TBK1 / IRF3 signaling pathway in lung cancer cells in vitro and increases the expression of type I interferon genes IFN-β1 and IFN-α2

[0042] To verify that ECM activates CD8 through the innate immune response pathway + T cells, LLC cells (purchased from the Chinese Academy of Sciences Cell Bank) and A549 cells (human lung adenocarcinoma cells, purchased from the Chinese Academy of Sciences Cell Bank) were used for in vitro experimental studies. Both cells were cultured in DMEM high-glucose complete medium (containing 10% FBS). When the two cells were in the logarithmic growth phase, the cells were inoculated at (3×10 5 , 1.5×10 5 ) were plated on a 6-well cell culture plate, and after the cells were cultured until they adhered to the wall, different concentrations of ECM were added to the experimental groups and the cells were cultured for 24 h. Total cell protein was extracted for Western blotting, or total cell RNA was extracted for real-time quantitative PCR. Figure 4 A and Figure 4 As shown in B, ECM can increase the levels of phosphorylated TBK1 (p-TBK1) and phosphorylated IRF3 (p-IRF3) in a dose-dependent manner, indicating that ECM can activate the cGAS / STING / TBK1 / IRF3 signaling pathway. Figure 4 As shown in C, ECM increased the expression of type I interferon genes IFN-β1 and IFN-α2 in LLC cells in a dose-dependent manner.

[0043] Activation of the cGAS / STING signaling pathway can promote the expression of type I interferon genes and interferon-stimulated genes (ISGs) through the IRF3 transcription factor, among which T cell chemokines IFN-α, IFN-β and CXCL10 can significantly increase CD8 + T cell infiltration in tumors.

[0044] Transwell co-culture system was used to investigate whether ECM enhances the CD8 proliferation of LLC cells +First, fresh spleens were extracted from C57 mice, the connective tissue membrane on the spleen was removed, and the spleen was ground with the frosted end of a glass slide under sterile conditions. The spleen was filtered and centrifuged using a 70 μm filter membrane, and red blood cell lysis buffer was added to remove red blood cells. + T cell isolation kit (Cat. No. K1303, containing CD8 + CD8 T cell biotin antibody and streptavidin magnetic beads), cell sorting column (catalog number HCSC-10), cell sorting magnetic pole (catalog number LSC-S1) and sorting bracket (catalog number SS01) were sorted. + T cells. CD8 + T cells were expressed as 1×10 6 / mL was added with anti-mouse CD3 (Cat. No. 100339, 2μg / mL), anti-mouse CD28 (Cat. No. 102115, 2μg / mL) produced by BioLegend and MouseIL-2 (Cat. No. CK24, 10ng / mL) produced by Nearshore Protein for in vitro amplification. When they grew to a certain number and were in the logarithmic growth phase, they were used for subsequent operations.

[0045] First, CCK8 cell activity assay was used to detect the effect of ECM on primary CD8 + T cell killing effect, take the above primary CD8 + T cells (8×10 4 / well) were plated in a 96-well plate and incubated with 1640 medium containing different ECM drug concentrations for 48 hours. Then CCK8 was added and incubated for 3 hours. The absorbance at 450 and 650 nm was measured with an ELISA reader, and the percentage of cell activity was calculated by comparing with the control group. Figure 5 As shown in A, ECM has a significant effect on CD8 + T cells had no obvious killing activity.

[0046] LLC cells (1×10 5 ) were plated in a 24-well plate. After the cells adhered to the plate, they were pretreated with ECM at different concentrations for 24 h. + T cells were inoculated into the Transwell chamber and continued to be cultured. After 24 hours, the chamber was discarded and the cells below were collected. After staining with anti-mouse CD8 flow cytometry antibody, CD8 in the same volume of cell suspension under different treatment groups was detected. + The number of T cells. Figure 5 A and Figure 5 As shown in B, ECM can significantly enhance CD8 + Migration ability of T cells.

[0047] In summary, the ethanol extract of Achyranthes bidentata can be used to prepare CD8 + Drugs that target T cells infiltrating solid tumors.

[0048] Example 4

[0049] This embodiment provides a method for promoting killing CD8 + The drug for T cell infiltration of solid tumors comprises an ethanol extract of ophiopogon japonicus and a pharmaceutically acceptable excipient / carrier. The drug can be prepared into one of oral liquid, pills, tablets, syrup and film.

[0050] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. Preparation of ethanol extract of goosegrass to promote cytotoxic CD8 + The use of a drug for treating T cell infiltration of solid tumors is characterized in that The ethanol extract of Herba Eupatoriae induces the expression of type I interferon genes by activating the cGAS / STING / TBK1 / IRF3 signaling pathway, thereby promoting CD8 + T cell infiltration of solid tumors.

2. The ethanol extract of the herb according to claim 1 is used in the preparation of a drug that promotes the killing of CD8 + The use of a drug for treating T cell infiltration of solid tumors is characterized in that The preparation method of the ethanol extract of the herb is as follows: S1. Add the dried sample powder of the whole herb of Goosegrass into anhydrous ethanol at a ratio of 1 g: 6 mL, soak overnight, and then perform ultrasonic extraction for 1 hour. After filtering the residue, the extract is collected into another conical flask; S2, collect the filtered drug residue into the original conical flask and add anhydrous ethanol and then ultrasonically extract again for 1 hour, filter the drug residue and collect the extract; S3. Repeat step S2 twice, combine the three extracts, place the extracts in a vacuum rotary evaporator to reduce pressure and recover ethanol, concentrate to a thick paste, and then use a vacuum freeze dryer to dry it into an extract to obtain an ethanol extract of Herba Lysimachiae.

3. A CD8-like protein that promotes cytotoxicity + A drug for T cell infiltration of solid tumors, characterized in that The invention comprises an ethanol extract of ophiopogon japonicus and a pharmaceutically acceptable excipient / carrier.

4. The cytotoxic CD8 promoter according to claim 3 + A drug for T cell infiltration of solid tumors, characterized by: The medicine is one of oral liquid, pill, tablet, syrup and film.

Citation Information

Patent Citations

  • Anticancer drug and compound for regulating PD-L1 expression quantity and application thereof

    CN111467383A

  • Application of centipeda minima alcohol extract in liver cancer resistance

    CN117883490A